To answer nancy_portland's question specifically:
From a clinical standpoint, Has anyone dealt with de novo is an area where we have good evidence.
The short answer: baseline labs + quarterly monitoring is the standard of care.
The longer answer involves understanding the mechanism of action at the receptor level, which I am happy to elaborate on if helpful.